NASDAQ:HCWB HCW Biologics (HCWB) Stock Price, News & Analysis $4.05 +0.01 (+0.25%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$4.06 +0.00 (+0.12%) As of 04:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HCW Biologics Stock (NASDAQ:HCWB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get HCW Biologics alerts:Sign Up Key Stats Today's Range$3.82▼$4.2650-Day Range$3.31▼$6.0252-Week Range$2.77▼$100.80Volume123,268 shsAverage Volume1.43 million shsMarket Capitalization$8.72 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingBuy Company Overview HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. Read More HCW Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreHCWB MarketRank™: HCW Biologics scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingHCW Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialHCW Biologics has a consensus price target of $35.00, representing about 764.2% upside from its current price of $4.05.Amount of Analyst CoverageHCW Biologics has received no research coverage in the past 90 days.Read more about HCW Biologics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of HCW Biologics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HCW Biologics is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about HCW Biologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.06% of the float of HCW Biologics has been sold short.Short Interest Ratio / Days to CoverHCW Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HCW Biologics has recently increased by 542.41%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHCW Biologics does not currently pay a dividend.Dividend GrowthHCW Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.06% of the float of HCW Biologics has been sold short.Short Interest Ratio / Days to CoverHCW Biologics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HCW Biologics has recently increased by 542.41%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.42 News SentimentHCW Biologics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for HCW Biologics this week, compared to 1 article on an average week.Search Interest10 people have searched for HCWB on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows2 people have added HCW Biologics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HCW Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders42.70% of the stock of HCW Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.96% of the stock of HCW Biologics is held by institutions.Read more about HCW Biologics' insider trading history. Receive HCWB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HCW Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HCWB Stock News HeadlinesHCW Biologics congratulates Wugen on equity financingSeptember 19, 2025 | msn.comHCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity FinancingSeptember 18, 2025 | globenewswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks. | American Alternative (Ad)HCW Biologics Inc.: HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal ...September 16, 2025 | finanznachrichten.deHCW Biologics Advances Lead Product Candidate HCW11-040 to Late Stage IND-Enabling Studies for Solid Tumor TreatmentSeptember 16, 2025 | quiverquant.comQHCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical DevelopmentSeptember 16, 2025 | globenewswire.comHCW Biologics Inc.: HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager ProgramSeptember 9, 2025 | finanznachrichten.deHCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager ProgramSeptember 9, 2025 | markets.businessinsider.comSee More Headlines HCWB Stock Analysis - Frequently Asked Questions How have HCWB shares performed this year? HCW Biologics' stock was trading at $17.8440 at the beginning of the year. Since then, HCWB shares have decreased by 77.3% and is now trading at $4.05. How were HCW Biologics' earnings last quarter? HCW Biologics Inc. (NASDAQ:HCWB) announced its quarterly earnings results on Monday, August, 18th. The company reported ($6.79) EPS for the quarter, missing analysts' consensus estimates of $1.80 by $8.59. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $7 million. When did HCW Biologics' stock split? Shares of HCW Biologics reverse split on the morning of Friday, April 11th 2025.The 1-40 reverse split was announced on Tuesday, April 1st 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did HCW Biologics IPO? HCW Biologics (HCWB) raised $45 million in an initial public offering on Tuesday, July 20th 2021. The company issued 5,600,000 shares at $8.00 per share. EF Hutton acted as the underwriter for the IPO and Revere Securities was co-manager. Who are HCW Biologics' major shareholders? HCW Biologics' top institutional shareholders include Golden State Wealth Management LLC (0.69%). Insiders that own company stock include Hing C Wong, Rebecca Byam, Lee Flowers and Gary M Winer. View institutional ownership trends. How do I buy shares of HCW Biologics? Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HCW Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HCW Biologics investors own include Jiuzi (JZXN), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Kiora Pharmaceuticals (KPRX), Rallybio (RLYB), Adial Pharmaceuticals (ADIL) and Aridis Pharmaceuticals (ARDS). Company Calendar Last Earnings8/18/2025Today9/23/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HCWB CIK1828673 Webwww.hcwbiologics.com Phone954-842-2024Fax954-842-2037Employees40Year Founded2018Price Target and Rating Average Price Target for HCW Biologics$35.00 High Price Target$35.00 Low Price Target$35.00 Potential Upside/Downside+764.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($14.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.02 million Net Margins-1,368.55% Pretax Margin-1,368.67% Return on EquityN/A Return on Assets-40.72% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.11 Sales & Book Value Annual Sales$2.57 million Price / Sales3.39 Cash FlowN/A Price / Cash FlowN/A Book Value($6.08) per share Price / Book-0.67Miscellaneous Outstanding Shares2,150,000Free Float1,233,000Market Cap$8.71 million OptionableNot Optionable Beta0.70 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:HCWB) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.